KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.

TitleKSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.
Publication TypeJournal Article
Year of Publication2006
AuthorsCannon M, Cesarman E, Boshoff C
JournalBlood
Volume107
Issue1
Pagination277-84
Date Published2006 Jan 01
ISSN0006-4971
KeywordsCell Cycle, Cell Line, Tumor, Cyclin-Dependent Kinase 2, Cyclin-Dependent Kinase Inhibitor p21, Herpesvirus 8, Human, Humans, Immediate-Early Proteins, Lymphoma, Non-Hodgkin, Pleural Effusion, Malignant, Receptors, Chemokine, Trans-Activators, Transcription, Genetic, Viral Proteins, Virus Replication
Abstract

Kaposi sarcoma (KS) remains the most common AIDS-associated malignancy worldwide. In sub-Saharan Africa especially, this aggressive endothelial-cell tumor is a cause of widespread morbidity and mortality. Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is now known to be an etiologic force behind KS and primary-effusion lymphoma (PEL). Over time, KSHV has pirated many human genes whose products regulate angiogenesis, inflammation, and the cell cycle. One of these, the KSHV vGPCR, is a lytic product that is a constitutively active homolog of the IL-8 receptor. Although it is considered a viral oncogene and causes KS-like lesions in mice, vGPCR expression results in cell-cycle arrest of KSHV-infected PEL cells. In the present study, we show that this arrest is mediated by p21 in a p53-independent manner; the resulting Cdk2 inhibition decreases the efficiency of chemical induction of KSHV lytic transcripts ORF 50 and 26. Importantly, Cdk2 activity is also essential for replication in other human herpesviruses. The ability of vGPCR to delay or abort KSHV replication may explain how despite being a lytic product, this potent signaling molecule has a vital role in tumor formation via its induction of various KS-associated cytokines.

DOI10.1182/blood-2005-06-2350
Alternate JournalBlood
PubMed ID16150942
PubMed Central IDPMC1895347
Grant ListCA068 939 / CA / NCI NIH HHS / United States
K08-AI53 971 / AI / NIAID NIH HHS / United States
Related Faculty: 
Ethel Cesarman, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700